Product candidate	Target indication	Development status
ZerenexTM (ferric citrate)	Hyperphosphatemia in patients with end-stage renal disease	Phase 3 Completed Jan 2013; Pending NDA and MAA submissions. Japan Phase 3 program completed by sublicensee (JT and Torii); Japanese NDA filed Jan 2013.
ZerenexTM (ferric citrate)	Management of serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease ("NDD-CKD")	Phase 2 initiated Nov 2012; Ongoing.